The release of phosphorylated-HSP27 from activated platelets of obstructive sleep apnea syndrome (OSAS) patients.


Journal

Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 17 07 2019
revised: 17 10 2019
accepted: 31 10 2019
pubmed: 16 12 2019
medline: 18 8 2020
entrez: 16 12 2019
Statut: ppublish

Résumé

Obstructive sleep apnea syndrome (OSAS) is a well known risk of arterial thrombosis that results in cardiovascular morbidity. It has been reported that platelet aggregability is enhanced in patients with OSAS. In the present study, we investigated whether phosphorylated-HSP27 is released from the activated platelets of OSAS patients. Patients diagnosed with OSAS (n = 21) were recruited, and platelet-rich plasma (PRP) was stimulated by ADP, ristosetin, collagen, and thrombin receptor-activating peptide. Platelet aggregation was measured using an aggregometer with a laser-scattering system. The levels of protein phosphorylation and the released levels of phosphorylated-HSP27 were determined by Western blot analysis and an ELISA, respectively. The phosphorylation of HSP27 in the platelets was induced by the stimulators. The released levels of phosphorylated-HSP27 was correlated with the levels of phosphorylated-HSP27 stimulated by ADP or collagen. The levels of ADP-induced phosphorylated-HSP27 were correlated with those of both phosphorylated-protein kinase B (Akt) and phosphorylatd-p38 mitogen-activated protein kinase; however, the levels of phosphorylated-HSP27 stimulated by collagen were correlated with phosphorylated-Akt levels only. The ED The results strongly suggest that phosphorylated-HSP27 is released from the activated platelets of OSAS patients.

Sections du résumé

BACKGROUND BACKGROUND
Obstructive sleep apnea syndrome (OSAS) is a well known risk of arterial thrombosis that results in cardiovascular morbidity. It has been reported that platelet aggregability is enhanced in patients with OSAS. In the present study, we investigated whether phosphorylated-HSP27 is released from the activated platelets of OSAS patients.
METHODS METHODS
Patients diagnosed with OSAS (n = 21) were recruited, and platelet-rich plasma (PRP) was stimulated by ADP, ristosetin, collagen, and thrombin receptor-activating peptide. Platelet aggregation was measured using an aggregometer with a laser-scattering system. The levels of protein phosphorylation and the released levels of phosphorylated-HSP27 were determined by Western blot analysis and an ELISA, respectively.
RESULTS RESULTS
The phosphorylation of HSP27 in the platelets was induced by the stimulators. The released levels of phosphorylated-HSP27 was correlated with the levels of phosphorylated-HSP27 stimulated by ADP or collagen. The levels of ADP-induced phosphorylated-HSP27 were correlated with those of both phosphorylated-protein kinase B (Akt) and phosphorylatd-p38 mitogen-activated protein kinase; however, the levels of phosphorylated-HSP27 stimulated by collagen were correlated with phosphorylated-Akt levels only. The ED
CONCLUSION CONCLUSIONS
The results strongly suggest that phosphorylated-HSP27 is released from the activated platelets of OSAS patients.

Identifiants

pubmed: 31838041
pii: S2212-5345(19)30113-3
doi: 10.1016/j.resinv.2019.10.006
pii:
doi:

Substances chimiques

Biomarkers 0
HSP27 Heat-Shock Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-127

Informations de copyright

Copyright © 2019 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Auteurs

Haruhiko Tokuda (H)

Department of Clinical Laboratory/Biobank of Medical Genome Center, National Center for Geriatrics and Gerontology, Obu, 474-8511, Japan; Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan. Electronic address: tokuda@ncgg.go.jp.

Masaaki Kusunose (M)

Department of Respiratory Medicine, National Center for Geriatrics and Gerontology, Obu, 474-8511, Japan.

Kazuyoshi Senda (K)

Department of Respiratory Medicine, National Center for Geriatrics and Gerontology, Obu, 474-8511, Japan.

Kumi Kojima (K)

Department of Clinical Laboratory/Biobank of Medical Genome Center, National Center for Geriatrics and Gerontology, Obu, 474-8511, Japan.

Takashi Onuma (T)

Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.

Akiko Kojima (A)

Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.

Daisuke Mizutani (D)

Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.

Yukiko Enomoto (Y)

Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.

Toru Iwama (T)

Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.

Hiroki Iida (H)

Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.

Osamu Kozawa (O)

Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH